Dr. Behfar Ehdaie

I had a fellow once who was really interested in kidney cancer and he goes, how do I become a kidney cancer expert in my institution when I'm going and there's five, six other people doing kidney cancer surgery? Well, I said, go to the cooperative group, bring a high-risk kidney cancer protocol to your institution. You don't need to be the one who wrote the protocol.

I had a fellow once who was really interested in kidney cancer and he goes, how do I become a kidney cancer expert in my institution when I'm going and there's five, six other people doing kidney cancer surgery? Well, I said, go to the cooperative group, bring a high-risk kidney cancer protocol to your institution. You don't need to be the one who wrote the protocol.

I had a fellow once who was really interested in kidney cancer and he goes, how do I become a kidney cancer expert in my institution when I'm going and there's five, six other people doing kidney cancer surgery? Well, I said, go to the cooperative group, bring a high-risk kidney cancer protocol to your institution. You don't need to be the one who wrote the protocol.

You just have to be the site PI, which the overall PI would love for you to do that. The protocol is written. You just need to enroll patients and now you can talk about your trial at your institution. You'll have patients directed to you who are eligible for that trial.

You just have to be the site PI, which the overall PI would love for you to do that. The protocol is written. You just need to enroll patients and now you can talk about your trial at your institution. You'll have patients directed to you who are eligible for that trial.

You just have to be the site PI, which the overall PI would love for you to do that. The protocol is written. You just need to enroll patients and now you can talk about your trial at your institution. You'll have patients directed to you who are eligible for that trial.

Well, thank you for that. And, you know, my interest in both research and clinical trials is very similar to, I'm sure, many urology residents and fellows who start their career. We want to make a big difference. We understand that retrospective papers and studies are important.

Well, thank you for that. And, you know, my interest in both research and clinical trials is very similar to, I'm sure, many urology residents and fellows who start their career. We want to make a big difference. We understand that retrospective papers and studies are important.

Well, thank you for that. And, you know, my interest in both research and clinical trials is very similar to, I'm sure, many urology residents and fellows who start their career. We want to make a big difference. We understand that retrospective papers and studies are important.

But ultimately, to understand the impact of any of our either decisions, interventions, we need to do randomized controlled trials. And those trials still remain the landmarks of our education when we look back at what we've learned. So our goal and many goals like mine was to just be able to contribute to the field in a small way. And the experience happened, you know, very early on in my career.

But ultimately, to understand the impact of any of our either decisions, interventions, we need to do randomized controlled trials. And those trials still remain the landmarks of our education when we look back at what we've learned. So our goal and many goals like mine was to just be able to contribute to the field in a small way. And the experience happened, you know, very early on in my career.

But ultimately, to understand the impact of any of our either decisions, interventions, we need to do randomized controlled trials. And those trials still remain the landmarks of our education when we look back at what we've learned. So our goal and many goals like mine was to just be able to contribute to the field in a small way. And the experience happened, you know, very early on in my career.

As you know, when I completed my fellowship in Memorial Sloan Kettering, I was ready to hit the ground running. And I was fortunate enough to understand that perhaps some areas of research that needed to be done were in both biopsies, this is pre-MR targeted biopsy era that was universally accepted, and focal therapy. And all that tied into my interest in active surveillance.

As you know, when I completed my fellowship in Memorial Sloan Kettering, I was ready to hit the ground running. And I was fortunate enough to understand that perhaps some areas of research that needed to be done were in both biopsies, this is pre-MR targeted biopsy era that was universally accepted, and focal therapy. And all that tied into my interest in active surveillance.

As you know, when I completed my fellowship in Memorial Sloan Kettering, I was ready to hit the ground running. And I was fortunate enough to understand that perhaps some areas of research that needed to be done were in both biopsies, this is pre-MR targeted biopsy era that was universally accepted, and focal therapy. And all that tied into my interest in active surveillance.

So I went to London and spent, you know, three to four months with Dr. Hash Ahmed and Dr. Mark Emberton. And it was astonishing to me to see how easily their system was set up for patient enrollment and clinical trials. I remember when I returned, I went to my research mentor, who was Andrew Vickers, here at Memorial.

So I went to London and spent, you know, three to four months with Dr. Hash Ahmed and Dr. Mark Emberton. And it was astonishing to me to see how easily their system was set up for patient enrollment and clinical trials. I remember when I returned, I went to my research mentor, who was Andrew Vickers, here at Memorial.

So I went to London and spent, you know, three to four months with Dr. Hash Ahmed and Dr. Mark Emberton. And it was astonishing to me to see how easily their system was set up for patient enrollment and clinical trials. I remember when I returned, I went to my research mentor, who was Andrew Vickers, here at Memorial.

And I had probably a full sheet schema for a clinical trial that probably had like eight rows, six columns, trying to answer four to five questions. And I thought it was just great. And I remember Andrew sitting back in his chair and going, you put a lot of thought in this, but... This is not how I would approach clinical trials.

And I had probably a full sheet schema for a clinical trial that probably had like eight rows, six columns, trying to answer four to five questions. And I thought it was just great. And I remember Andrew sitting back in his chair and going, you put a lot of thought in this, but... This is not how I would approach clinical trials.